Therefore, here, we used an advanced CTC enrichment identification technology Canpatrol® System to detect CTCs as well as IMP3 expression in CTCs of osteosarcoma patients (27) and analyzed the relationship between CTCs and the clinicopathological characteristics of osteosarcoma patients to explore whether CTCs could be used as a biomarker for prognosis or metastasis prediction of osteosarcoma. This evidence concerns the gene IMP3 and osteosarcoma.